Morgan Stanley analyst Maxwell Skor lowered the firm’s price target on Ultragenyx (RARE) to $50 from $55 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx: Trial Setback Creates Buying Opportunity as Diversified Pipeline and Commercial Base Support $60 Target
- Ultragenyx price target lowered to $60 from $80 at H.C. Wainwright
- Ultragenyx price target lowered to $52 from $64 at Guggenheim
- Ultragenyx price target lowered to $58 from $72 at BofA
- Ultragenyx completes BLA filing for GSDIa gene therapy